Companies › Flare Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| FX-909 PPARG transcription inhibitor (basal- and ligand-activated) | PPARG | Phase 1 | Advanced Urothelial Carcinoma | Oct 2027 |
| FX-111 | – | Phase 1 | Metastatic Castration Resistant Prostate Cancer | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05929235 | FX-909 | Phase 1 | Advanced Urothelial Carcinoma | Oncology | Oct 2027 |
| NCT07719361 | FX-111 | Phase 1 | Metastatic Castration Resistant Prostate Cancer | Oncology | Feb 2028 |
Zydus Therapeutics Boryung Pharmaceutical Minoryx Therapeutics Dong Wha Pharmaceutical Inventiva Pharma
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.